News

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference

January 2019

Ability Pharmaceuticals, SL announced today that Carles Domènech, PhD, Chief Executive Officer and co-Founder, will be attending the 4th BIOMED EVENT® by INVEST SECURITIES on Tuesday, January 22, 2019 in Paris. The conference is highly transactional, bringing together an exciting cross-section of small-cap venture-funded companies with leading investors, pharmas, and investment service providers.

Besides that, Hector Perez-Montoyo, PhD,  Biological Research Director, is attending the 2019 Cholangiocarcinoma Foundation Annual Conference from January 30th to February 2nd, 2019 in Salt Lake City, Utah, USA. The Cholangiocarcinoma Foundation's annual program seeks to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma. 
 

LATEST NEWS

04.02.2019

News

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

News

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG